The Pharmacokinetic Pattern of Glycosylated Human Recombinant Lymphotoxin (LT) in Rats after Intravenous Administration
スポンサーリンク
概要
- 論文の詳細を見る
We have examined the pharmacokinetics of glycosylated recombinant human lymphotoxin (LT) after intravenous bolus injection in rats and compared them with those of tumor necrosis factor (TNF) or LT species. The results are as follows. 1) The mean half-life of glycosylated LT in serum increases for each increase in dose, and the distribution volume (V) and total body clearance [(Cl (total)] tend to decrease for increase in dose. On the other hand, the half-life of TNF also increases for increase in dose, but the V tends to increase for increase in dose and Cl (total) does not change. 2) The glycosylated LT distributes to all organs so far tested except brain, and tends to accumulate to kidney more than other tissues at 6 h after the injection. 3) Nonglycosylated LT produced by E. coli and the glycosylated LT species carrying both N-type and mucin-type sugar moieties (25 kDa LT) have shorter half-lives and higher Cl (total) s than 23 kDa LT carrying N-type sugar moieties alone. The 21 kDa LT, the same species as 23 kDa LT except that it lacks 15 amino acid residues at the N-terminus, disappears much faster than 23 kDa LT and shows higher V and Cl (total). Thus, glycosylated LT shows nonlinear pharmacokinetics like TNF, but the deposition is quite different from that of TNF. The high serum concentration of glycosylated LT depends upon the presence of N-type sugar moieties, but not mucin-type sugar moieties. The N-terminal protein chain of LT also correlates with the serum concentration.
- 公益社団法人日本薬学会の論文
著者
-
Asahi Takashi
Biochemical Research Laboratories Kanegafuchi Chemical Industry Co. Ltd.
-
Kakutani Tetsu
Biochemical Research Laboratories Kanegafuchi Chemical Industry Co. Ltd.
-
KAWAHARADA Hajime
Biochemical Research Laboratories, Kanegafuchi Chemical Industry Co., Ltd.
-
WATANABE Kiyoshi
Biochemical Research Laboratories, Kanegafuchi Chemical Industry Co., Ltd.
-
Watanabe Kiyoshi
Biochemical Research Laboratories Kanegafuchi Chemical Industry Co. Ltd.
-
Watanabe Kazuyoshi
Faculty Of Pharmaceutical Sciences Toyama Medical And Pharmaceutical University:institute Of Cytosig
-
Kajikawa Tamio
Biochemical Research Laboratories Kanegafuchi Chemical Industry Co. Ltd.
-
Yamashita Toshiaki
Biochemical Research Laboratories Kanegafuchi Chemical Industry Co. Ltd.
-
KAWATSU Masaji
Biochemical Research Laboratories, Kanegafuchi Chemical Industry Co., Ltd.
-
TAKEO Kazuyuki
Biochemical Research Laboratories, Kanegafuchi Chemical Industry Co., Ltd.
-
FUNAHASHI Iwao
Biochemical Research Laboratories, Kanegafuchi Chemical Industry Co., Ltd.
-
Funahashi Iwao
Biochemical Research Laboratories Kanegafuchi Chemical Industry Co. Ltd.
-
Takeo Kazuyuki
Biochemical Research Laboratories Kanegafuchi Chemical Industry Co. Ltd.
-
Kawatsu M
M.c.r.f. Shizuoka Jpn
-
Watanabe K
Kureha Biomedical Research Lab. Tokyo Jpn
-
Kawaharada H
Biochemical Research Laboratories Kanegafuchi Chemical Industry Co. Ltd.
-
Kawaharada Hajime
Biochemical Research Laboratories Kanegafuchi Chemical Industry Co. Ltd.
-
Watanabe Koju
Kureha Biomedical Research Laboratories:department Of Orthopedic Surgery National Defense Medical Co
関連論文
- Constitutive High-level Production of Human Lymphotoxin by CHO-K1 Cells Transformed with the Human Lymphotoxin Gene Controlled by a Human β-Actin Promoter(Biological Chemistry)
- Comparison of Human Lymphotoxin Gene Expression in CHO Cells Directed by Genomic DNA or cDNA Sequences(Biological Chemistry)
- Asymmetric Hydrolysis of (dl)-1-Acyloxy-2-halo-1-phenylethanes with Lipases(Organic Chemistry)
- Lipase-catalyzed Stereoselective Hydrolysis of 2-Acyl and 1-p-Tolylsulfonyl Substituted Propanediol and Butanediol
- Stereochemical Inversion of (R)-5-Hydroxymethyl-3-tert-butyl-2-oxazolidinone or (R)-5-Hydroxymethyl-3-isopropyl-2-oxazolidinone to the Corresponding (S)-Isomer
- Microbial Production of (R)-3-Halolactic Acid from(±)-3-Halo-1,2-Propanediol
- Stereospecific Hydrolysis of 2-Oxazolidinone Esters and Separation of Products with an Immobilized Lipase Column
- Production of D-β-Hydroxycarboxylic Acids from the Corresponding Carboxylic Acids by a Mutant of Candida rugosa : Studies of β-Hydroxycarboxylic Acids (V)
- Production of β-Hydroxypropionic Acid from Propionic Acid by a Candida rugosa Mutant Unable to Assimilate Propionic Acid : Studies on β-Hydroxycarboxylic Acids (IV)
- Production of d-β-Hydroxyisobutyric Acid from Isobutyric Acid by Candida rugosa and Its Mutant : Studies on β-Hydroxycarboxylic Acids (III)
- Produciton of β-Hydroxycarboxylic Acids from Aliphatic Carboxylic Acids by Microorganisms : Studies on β-Hydroxycarboxylic Acids (II)
- Stereoselective Conversion of Isobutyric Acid to β-Hydroxyisobutyric Acid by Microoganisms : Studies on β-Hydroxycarboxylic Acids (I)
- EFFECT OF PROTEINASE INHIBITORS HAVING ANTIINFLAMMATORY ACTIVITY ON GELATINASE, ELASTASE AND CATHEPSIN G ISOLATED FROM RAT POLYMORPHONUCLEAR LEUKOCYTES
- Changes in the Levels of Rat Interleukin 8/CINC and Gelatinase in the Exudate of Carrageenin-Induced Inflammation in Rats
- ANTI-INFLAMMATORY EFFECT OF A SELECTIVE INHIBITOR OF ELASTASE, CATHEPSIN G AND CHYMOTRYPSIN ON CARRAGEENIN-INDUCED INFLAMMATION IN RATS
- PROTEINASE INHIBITORS SUPPRESS THE FORMATION OF GRANULATION TISSUE IN THE CARRAGEENIN-INDUCED INFLAMMATION IN RATS
- Inhibitory Action of Synthetic Proteinase Inhibitors and Substrates on the Chemotaxis of Rat Polymorphonuclear Leukocytes in Vitro
- ALPHA-ADRENOLYTIC PROPERTIES OF APOGALANTHAMINE AND AZAPETINE ANALOGS
- Enzymatic Resolution of 2-Oxazolidinone Estersf
- The Pharmacokinetic Pattern of Glycosylated Human Recombinant Lymphotoxin (LT) in Rats after Intravenous Administration
- Effect of Benzylidene Derivative (Novel Antirheumatic Agent) on Chondrocyte Metabolism
- Lipase-catalyzed Stereoselective Hydrolysis of 2-Acyloxy-3-chloropropyl p-toluenesulfonate
- Asymmetric Hydrolysis of (R, S)-5-Acetoxymethyl-3-terr-butyl-oxazolidin-2-one with Enzymes and Microorganisms
- Effect of .ALPHA.-(3,5-di-tert-butyl-4-hydroxybenzylidene)-.GAMMA.-butyrolactone (KME-4), a new anti-inflammatory drug, on the established adjuvant arthritis in rats.
- Pharmacological properties of a new anti-inflammatory compound, .ALPHA.-(3,5-di-tert-butyl-4-hydroxybenzylidene)-.GAMMA.-butyrolactone (KME-4), and its inhibitory effects on prostaglandin synthetase and 5-lipoxygenase.
- Inhibition of polymorphonuclear leukocyte 5-lipoxygenase and platelet cyclooxygenase by .ALPHA.-(3,5-di-tert-butyl-4-hydroxybenzylidene)-.GAMMA.-butyrolactone (KME-4), a new anti-inflammatory drug.
- Synthesis of (S)-β-Blockers from (S)-5-Hydroxymethyl-3-tert butyl-2-oxazolidinone or (S)-5-Hydroxymethyl-3-isopropyl-2-oxazolidinone